Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EURAMOS-1 osteosarcoma treatment optimization trial
2004-000242-20Phase 3Completed
- Sponsor
- Specialty Solutions Group
- Start
- Jan 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate, doxorubicin, cisplatin, ifosfamide, etoposide and 1 more in osteosarcoma (OS) (4 arms), sponsored by Specialty Solutions Group. Primary endpoint: Event-free survival. Started Jan 2005; status: completed.
02
Drugs
methotrexatedoxorubicincisplatinifosfamideetoposide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2004-000242-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000242-20.